Site Search

You searched for "hepatitis D"

• Đọc về chiến dịch mới ra mắt “Learn the Link” của Hepatitis B Foundation cùng Cô Dung Hứa của Hội Ung Thư Việt Mỹ (VACF)

                    Tháng này, chúng tôi có dịp trò chuyện với cô Dung Hứa của Vital Access Care Foundation, hay còn được biết đến với tên Vietnamese American Cancer Foundation – Hội Ung Thư Việt Mỹ. Cô Dung và đội ngũ VACF liên tục làm việc để trợ giúp nhu cầu của cộng đồng người Việt tại Quận Cam, California và các khu vực lân cận. Cô Dung cho chúng tôi biết về các kinh nghiệm trong việc ngăn ngừa bệnh viêm gan B và ung thư gan trong cộng đồng, cũng như sự đóng góp vào chiến dịch Learn the Link, chính thức khởi động vào tháng 2 năm 2024. Cô Dung chia sẻ những thử thách mà mình phải đối mặt, những trải nghiệm quý giá và nhiều cách cô ấy làm việc để kết nối và nâng cao hiểu biết cho cộng đồng.  Chiến dịch Learn the Link được tạo ra nhằm nâng cao nhận thức về mối liên hệ giữa bệnh viêm gan B mãn tính và ung thư gan một cách phù hợp về mặt văn hoá cho các cộng đồng chịu ảnh hưởng nặng nề nhất. Chiến dịch được thông tin thông qua việc trực tiếp nói chuyện với các thành viên trong cộng đồng và được xây dựng với việc tập trung và ưu tiên các nhu cầu của họ. Hepatitis B Foundation – Quỹ Viêm Gan B đã tổ chức các nhóm thảo luận và thành lập một ban cố vấn để tìm hiểu về nhu cầu và lo ngại của cộng đồng, qua đó tạo ra tài liệu tham khảo thích hợp với các nền văn hoá khác nhau.  Cô có thể giới thiệu về bản thân và cơ quan của cô được không?  Tên tôi là Dung và tôi hiện đang làm việc tại Vital Access Care Foundation – Hội Ung Thư Việt Mỹ. VACF vừa chính thức đổi sang tên tiếng Anh mới vì đã mở rộng các

  http://www.hepb.org/blog/doc-ve-chien-dich-moi-ra-mat-learn-link-cua-hepatitis-b-foundation-cung-co-dung-hua-cua-hoi-ung-thu-viet-vacf/
• Join the Conversation at the Hep B United Summit; Watch Summit Sessions On Facebook Live!

  The annual Hep B United Summit, organized by the Hepatitis B Foundation, convenes in Washington D.C. from Thursday, July 27 through Friday, July 28. National and local coalition partners, experts, stakeholders, and federal partners will meet to discuss how to increase hepatitis B testing and vaccination and improve access to care and treatment for individuals living with hepatitis B. You can watch many of these important sessions on Facebook Live. You can also follow the conversation at the Summit on Twitter with #Hepbunite! Facebook Live is live video streaming available to all Pages and profiles on Facebook. Check out the agenda below and go to the HepBUnited Facebook Page to view the live broadcast. The session will be made available following the broadcast for those who are not able to join us live. Here are the details on the sessions that will be broadcast on Facebook Live: Day 1 – Thursday July 27: 8:30 – 10:00 AM:  Welcome and Introductions Tim Block, PhD, President & Co-founder, Hepatitis B Foundation and Baruch S. Blumberg Institute, Chari Cohen DrPH, MPH, Co-Chair, Hep B United and Director of Public Health, Hepatitis B Foundation, Jeff Caballero, MPH, Co-Chair, Hep B United and Executive Director, AAPCHO 10:00 – 10:30 AM:  Time to Eliminate Hepatitis B Dr. John Ward, Director, CDC Division of Viral Hepatitis  10:30 -11:15 AM:  #justB Storytelling Campaign Panel: Real People Sharing their Stories of Hepatitis B Rhea Racho, MPP, Public Health Program and Policy Coordinator, Hepatitis B Foundation and storytellers 11:15 - 12:00 PM: Know Hepatitis B Campaign Updates Cynthia Jorgenson, DrPH, Team Lead and Sherry Chen, MPH, Health Scientist, Division of Viral Hepatitis, Centers for Disease Control and Prevention 12:00 – 12:30 PM:  Increasing Community Awareness and Education Moderator: Catherine Freeland, MPH, Hepatitis B Foundation and Sherry Chen, CDC 3:00 PM – 4:15 PM:  Breakout Session: Increasing Awareness through Media

  http://www.hepb.org/blog/join-conversation-hep-b-united-summit-watch-summit-facebook-live/
• Hepatitis B Foundation Launches Education Initiative for People Coinfected with Hepatitis B and D

  By Sierra Pellechio The Hepatitis B Foundation is excited to launch the Hepatitis Delta Connect program to provide education and resources for patients and families affected by hepatitis D, the most aggressive form of viral hepatitis. Hepatitis D infection requires the presence of the hepatitis B surface antigen (HBsAg), so only people already infected with hepatitis B can become infected with hepatitis D. There is a large gap in knowledge and awareness about this virus, and the foundation is working to provide easily-accessible information and support to those in need. Because the hepatitis D virus (HDV) is acquired only if a hepatitis B infection is present, it can be effectively prevented through hepatitis B vaccination. While hepatitis D is not common in the United States, worldwide it affects 15-20 million people. Areas with the highest rates of hepatitis D infection rate include China, Russia, the Middle East, Mongolia, Romania, Georgia, Turkey, Pakistan, Africa and the Amazonian river basin. It is transmitted through direct contact with infected blood and bodily fluids, and most commonly affects high-risk groups such as intravenous drug users, men who have sex with men or have multiple sexual partners, and people emigrating from countries where hepatitis D is common. Hepatitis D can be acquired either through coinfection (becoming infected with hepatitis D and B at the same time) or a super-infection (becoming infected with hepatitis D after a person has hepatitis B). A coinfection generally resolves spontaneously after about six months, but it can sometimes result in life-threatening or fatal liver failure. Like hepatitis B, hepatitis D may not present with any symptoms, so getting a simple blood test is the only way to know if you are infected. Treatment options are limited, but pegylated interferon has shown some effectiveness in a small percentage of patients (less than 30 percent). The good news is that there are five promising drugs currently in

  http://www.hepb.org/blog/hepatitis-b-foundation-launches-education-initiative-people-coinfected-hepatitis-b-d/
• Join the Conversation at the Hep B United Summit; Watch the Summit On Periscope!

  The annual Hep B United Summit, organized by the Hepatitis B Foundation, convenes in Washington D.C. from Wednesday, July 27 through Friday, July 29. National and local coalition partners, experts, stakeholders, and federal partners will meet to discuss how to increase hepatitis B testing and vaccination and improve access to care and treatment for individuals living with hepatitis B. You can watch many of these important sessions LIVE on Periscope. You can also follow the conversation at the Summit on Twitter with #Hepbunite! What is Periscope? Periscope broadcasts live video worldwide, in real time, so you can watch it from your computer (via web link) or a mobile device (via Periscope app). The app is free and available for your phone (iPhone and Android) and iPad or Tablet. Wondering how to use Periscope to watch the Hep B United Summit in real time? There are two options: If you’re using a PC, keep an eye out for a tweet from Hep B United and/or the Hepatitis B Foundation Twitter handles (@hepbunited or @hepbfoundation) that will contain a link to take you directly to the stream. If you’re on the go, you can download the Periscope app for free from the App store or Google Play. You can either login using Twitter or directly with your phone number. Create your Periscope username and then follow hepbunited and hepbfoundation. We’ll be sure to follow you back! Here’s a great Periscope tutorial from Traffic Generation Café to get you started. You can also click on the link from your twitter app. Here are the details on the sessions that will be broadcast on Periscope: State of Hepatitis B 1:45-2:15 p.m. Wednesday: Brian McMahon, MD, will provide an update on the state of hepatitis B globally, via a GoToMeeting connection. Click and watch later here.  Hep B United and Know Hepatitis B Campaign Accomplishments 2:15-3 p.m. Wednesday:  Cynthia Jorgensen, DrPH, of the CDC’s Division of Viral Hepatitis will provide an update on Hep B United and

  http://www.hepb.org/blog/join-conversation-hep-b-united-summit-watch-summit-periscope/
• Comprehensive hepatitis B program in Vietnam provides an excellent model for other countries

  Doylestown, Pa., Dec. 15, 2022 - Vietnam is among the nations with the heaviest burden of hepatitis B, with at least 8% of people infected, studies have shown. The prevalence may be closer 10%, according to Doan Y. Dao, MD, a native of Vietnam, and assistant professor at Johns Hopkins University School of Medicine. That means with a population of approximately 100 million, nearly 10 million residents may be living with hepatitis B, which in part is why Dr. Dao went into the field of hepatology and has focused on hepatitis. “It began with a family, personal reasons,” Dr. Dao said. “Then I decided during medical school to take time and learn more, investigate and study about hepatitis B. When I saw the statistics, I decided to return to where I came from to experience firsthand the disease burden with the patients in Vietnam.”   [Note: You can hear Dr. Dao’s story, in his own words, in a recent episode of B Heppy, the Hepatitis B Foundation’s podcast. Click here.] Dr. Dao contacted Joan and Tim Block, co-founders of the Hepatitis B Foundation, “for advice and support.” The Blocks were able to provide seed funding from the Foundation to help Dr. Dao launch start the Vietnam Viral Hepatitis Alliance in 2014. Aimed at reducing the public health burden of hepatitis B and hepatitis C viruses, the Alliance is focused on supporting the design, funding and implementation of research-based awareness, education, screening and access-to-care programs, along with educational programs for individuals in community and health professionals. Chari A. Cohen, DrPH, MPH, president of the Hepatitis B Foundation says Dr. Dao’s work is “cutting-edge” and he represents “the next generation of clinician-researchers. “With the initiatives he has developed in Vietnam, Dr. Dao has created an excellent model for eliminating hepatitis B that other countries can use,” Dr. Cohen said. “He’s the future of hepatitis B.Dr. Lily-Trang Pham of the Vietnam Viral Hepatitis Alliance speaking with Foundation Co-founder Joan Block at the 2017 Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Dr. Lily-Trang Pham of the Vietnam Viral Hepatitis Alliance speaking with Foundation Co-founder Joan Block at the 2017 Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. In 2017, the Alliance was granted an international NGO status by Vietnam’s Department of State. Dr. Dao was invited to join the faculty of the Johns Hopkins University School of Medicine in 2020 and the university created its Center of Excellence for Liver Disease in Vietnam, which builds on the Alliance’s foundation and he directs. The most ambitious joint initiative of the Center and the Alliance is in Ho Chi Minh City. It’s a comprehensive demonstration program to screen and navigate access to care for 20,000 adults throughout Ho Chi Minh City, which has 10 million residents. Dr. Dao says it is Vietnam’s first community-based comprehensive screening and care access program. The result of this program sets the stage for their next provisional program that aims to eliminate hep B and C for 1.1 million residents of the section known as Thu Duc City, a section of Ho Chi Minh City. The Alliance launched the Hepatitis Evaluation to Amplify Testing and Treatment (HEAT) program in Vietnam in 2020 in collaboration with the Coalition for Global Hepatitis Elimination at the Task Force for Global Health. They also are working with the Division of Viral Hepatitis Laboratory, U.S. Centers for Disease Control and Prevention (CDC), to determine the burden and characterize the molecular epidemiology of hepatitis D in Ho Chi Minh City. Guided by a coalition of local stakeholders, the Alliance has been coordinating the support of expanded hepatitis B and C testing and treatment efforts across Vietnam. The hope to “identify feasible strategies to scale testing and proven models of care” and “develop policy recommendations to inform further program development.” The ultimate goal is a long-term public-private partnership to implement public health policies that address the burden of viral hepatitis in Vietnam and work towards viral hepatitis elimination by 2030. For World Hepatitis Day this year, the Alliance conducted screening in Ho Chi Minh City, an annual tradition they call “Healthy Liver, Happy Life,” which began in 2018. The Alliance also sponsored a scientific conference, also an annual July 28 tradition. "The people of Vietnam understand they have a serious problem with hepatitis B,” Dr. Dao says. However, there are still two major misconceptions in the community that have made progress difficult. One is that treatment will not cure hepatitis B, “So why bother?” The second, he says, is the belief that the indolent or silent phase of the disease does not require treatment. Also challenging their efforts to combat hepatitis B in Vietnam, Dr. Dao says, are two issues facing probably everyone in the field worldwide: funding and stigma. Still, he remains optimistic. ”We have the testing, the effective vaccines and the effective treatments. If we put it all together, hepatitis B can be controlled and eliminated in the near future.”

  https://www.hepb.org/news-and-events/news-2/comprehensive-hepatitis-b-program-in-vietnam-provides-an-excellent-model-for-other-countries/
• Join Hep B United and Watch the Hep B Summit Online!

  The Hep B United Summit in Washington D.C., starting Sunday afternoon and running through Monday, July 26 and 27, can be viewed LIVE and in real time on Periscope. Plus, you can follow the conversation on Twitter with #HepBSummit! The 3rd annual Summit, organized by the Hepatitis B Foundation, will convene national and local coalition partners, experts, stakeholders, and federal partners to discuss goals and share strategies to increase hepatitis B testing and vaccination and improve access to care and treatment for individuals living with hepatitis B. Now, you can watch these important proceedings on Periscope. What is Periscope? Periscope broadcasts live video worldwide, in real time, so you can watch it from your computer (via web link) or a mobile device (via Periscope app). The app is free and available for your phone (iPhone and Android) and iPad or Tablet. (@Periscopeco) Wondering how to use Periscope to watch the Hep B United Summit in real time? There two options: If you’re using a PC, keep an eye out for a tweet from Hep B United’s Twitter handle (@hepbunited) that will contain a link to take you directly to the stream. If you’re on the go, you can download the Periscope app for free from the App store or Google Play. You can either login using Twitter or directly with your phone number. Create your Periscope username and then follow Hep B United / hepbunited. We’ll be sure to follow you back! Here’s a great Periscope tutorial from Traffic Generation Café to get you started ***Live commenting is only available if you are using the Periscope app on iOS or Android Wondering which sessions will be broadcast live from the #HepBSummit? Here’s a list, all events are Sunday and Monday, July 26 and 27, ET. HBU Summit Overview 3-3:30 p.m. Sunday: Joan Block (HBF) and Jeff Caballero (AAPCHO), Co-Chairs of Hep B United will go over the Summit Agenda and Objectives HBU Accomplishments and Strategies 3:30-4 p.m. Sunday:  Chari Cohen and Kate Moraras

  http://www.hepb.org/blog/join-hep-b-united-and-partners-at-the-hep-b-summit/
• Hepatitis B Foundation announces recipient of 2021 Baruch S. Blumberg Prize

  Dr. Wenhui Li of China's National Institute of Biological Sciences to be honored for contributing to the science of hepatitis B  Doylestown, Pa., Nov. 12, 2020 -- The Hepatitis B Foundation is announcing today that Wenhui Li, Ph.D., has been chosen as the recipient of its 2021 Baruch S. Blumberg Prize for outstanding contributions to advance the science and medicine of hepatitis B. An investigator at China’s National Institute of Biological Sciences (NIBS), Dr. Li is being recognized for his discovery of the hepatitis B virus (HBV) receptor on hepatocytes, a breakthrough that will have a major influence on the future of therapeutics for people living with chronic hepatitis B infections.  Wenhui Li, Ph.D. The Baruch S. Blumberg Prize is the Hepatitis B Foundation’s highest honor, given to publicly recognize the outstanding contributions made by an individual to significantly advance the science and medicine of hepatitis B. Considered to be the “Nobel Prize” for hepatitis B research, the award is named for Baruch S. Blumberg, M.D., D.Phil., who received the Nobel Prize in Medicine and Physiology in 1976 for discovering the hepatitis B virus (HBV). Dr. Blumberg, who was a co-founder of the Hepatitis B Foundation, died in 2011. The Foundation’s research arm, the Baruch S. Blumberg Institute, is named in his honor. “The community owes a tremendous debt to Dr. Li for his pioneering work in the discovery of the receptor for hepatitis B,” said Timothy S. Block, Ph.D., president and co-founder of the Hepatitis B Foundation and its Baruch S. Blumberg Institute. “Dr. Li’s work has been among the most important in the field.” Two Nobel Prize winners with ties to the Hepatitis B Foundation also praised Dr. Li’s selection. Dr. Harvey Alter, who is among the Foundation’s Scientific and Medical Advisors and a Blumberg Institute distinguished faculty member (adjunct), and Dr. Charles Rice, a Blumberg Institute advisor, who together were chosen for the 2020 Nobel Prize in Physiology or Medicine with collaborator Dr. Michael Houghton, spoke highly of Dr. Li’s research. “As the HBV story continues to unfold, Dr. Li has added a new important piece,” Dr. Alter said. “He has identified the receptor for HBV entry into liver cells providing the rationale for receptor-blocking therapeutics. I am very receptive to Dr. Li’s great discovery.” Dr. Rice commented: "This is a most fitting recognition for a truly transformative discovery. The search for the elusive HBV receptor spanned decades, tackled by some of the best labs in the world, and met with dismal failure. Wenhui and his team’s success has provided a remarkable new tool for HBV virology and re-energized the field to finally find a functional cure for chronic hepatitis B. Bravo!"   Nathaniel Brown, M.D., a retired pharmaceutical executive and global leader in the field of antiviral drug R&D focused on HBV and HCV, said: “Wenhui Li is a great choice. As Tim Block has pointed out, the HBV receptor was elusive for many years, and understanding HBV’s entry mechanism is helping to identify potential new therapeutics as well as providing a more precise understanding of HBV’s pathophysiology.”  Dr. Li said: “I feel extremely honored to be selected as the recipient of 2021 Baruch S. Blumberg Prize and the honor also goes to my colleagues working with me. I am very pleased that the work on receptor helps our understanding of HBV infection and with developing new therapies.” The Blumberg Prize recipient is chosen by the Hepatitis B Foundation’s Scientific and Medical Advisors. Also voting on the award are past recipients of the Blumberg Prize, including Dr. Harvey Alter, who is among the winners of the 2020 Nobel Prize in Medicine and Physiology; Dr. Anna Lok, assistant dean for clinical research, University of Michigan Medical School; and Dr. John Taylor, professor emeritus, Fox Chase Cancer Center. After earning a Ph.D. in 2001 from the Peking Union Medical College and the Chinese Academy of Medical Sciences, Dr. Li worked as a postdoctoral fellow and then as an instructor at Harvard Medical School, Boston. In 2007, he joined NIBS Beijing, where he has focused on viral infection of hepatitis B and hepatitis D. Dr. Li’s research led to the discovery that a multiple transmembrane bile acids transporter (NTCP, sodium taurocholate co-transporting polypeptide), predominantly expressed in liver, is a functional receptor for HBV and HDV. Dr. Li is now an investigator at NIBS and a professor at the Tsinghua Institute of Multidisciplinary Biomedical Research. The Hepatitis B Foundation is announcing Dr. Li’s selection for the Blumberg Prize during a virtual reception this evening (Nov. 12) for participants in The Liver Meeting, which is the annual meeting of the American Association for the Study of Liver Diseases that will be an online-only event this year. The Blumberg Prize is presented annually at the Hepatitis B Foundation’s Crystal Ball Gala, which typically attracts more than 200 leaders from academia, government, business and the regional community. This year’s Gala is scheduled for April 30.  # # # About the Hepatitis B Foundation: The nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy, the Hepatitis B Foundation is based in Doylestown, Pa. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. To donate, contact Jean Holmes at 215-489-4900 or jean.holmes@hepb.org.

  https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-announces-2021-baruch-s-blumberg-prize/
• Public Health and International Programs

  Elimination of hepatitis B is the ultimate goal of the Hepatitis B Foundation and the focus of our public health programs. To achieve this goal, we have developed successful community-based programs to increase vaccination, screening and linkage to care to stop the spread of this deadly virus. To harness the community energy and maintain the momentum, we are building coalitions at the local, national and international levels to improve capacity to ensure that every person knows their hepatitis B status and has access to the care they need to prevent a new infection or treat a chronic infection. Making hepatitis B history is what we aim to do. OUR LOCAL IMPACT: Philadelphia Hep B Coalition In 2008 the HBF created a program to address hepatitis B in its own backyard –Philadelphia. Over the past years the Philadelphia Hep B Coalition has grown into a thriving hepatitis B coalition of 75 members that work together in high-risk communities to educate, screen and link individuals to care. It has also become a model to test promising best practices to improve health outcomes around hepatitis B nationwide. Philadelphia Hep B Coalition (2015-2016) 54 education and screening events 2,400 people screened 80% of those infected linked to care 500 doses of free hepatitis B vaccine administered    Philadelphia Hep B United Coalition OUR NATIONAL IMPACT:Hep B United The HBF, in partnership with the Association of Asian Pacific Community Health Organizations (AAPCHO), created and co-chairs Hep B United, a national coalition of local coalitions across the country working together to increase hepatitis B awareness, screening, vaccination and linkage to care in their own communities. Currently, there are more than 30 members in 26 cities and 15 states. Hep B United is also proud to be an official partner of the Centers for Disease Control and Prevention and is co-branded with its Know Hepatitis B campaign, their first national multilingual awareness campaign on hepatitis B in the U.S. Hep B United (2016) 30 member coalitions in 26 cities across 15 states 4 million Asian Americans reached 13,000 educational sessions provided 40,000 people screened 47 volunteers participate in the National Speakers Bureau with 9 languages represented   OUR INTERNATIONAL IMPACT Haimen City, China Haimen City Program Launch The HBF’s citywide Hepatitis B Awareness Campaign in Haimen City is the first of its kind in China and was started in 2011. The campaign included educating the entire city’s population of 1.1 million people, all of the physicians and schools nurses, and most of the elected officials and community leaders. During one 12-month period, all pregnant women were screened for hepatitis B, and all newborns of infected women received the hepatitis B vaccine and HBIG to prevent a chronic infection. In addition, 12,000 people were screened for hepatitis B over three months, and 1,800 (15%) tested positive for hepatitis B. Most of these patients enrolled in the HBF’s Patient Empowerment Program, which provides educational materials and strategies to empower patients to take control of their health care and to partner with their physicians to avoid the long-term complications associated with hepatitis B. This program is funded by the Bristol-Myers Squibb Foundation and Haimen City Center for Disease Control. As we look to the future, we are sharing the lessons learned, best practices developed and strategies for building coalitions through peer-reviewed publications and presentations at professional conferences.  Haimen City, China 1.1 million (100%) residents educated 1,441 (90%) healthcare providers trained 5,407 (100%) pregnant women screened over 12 months 12,000 peoplescreened for hepatitis B over 3 months 1,800 people (15%) tested positive for hepatitis B 1,382 (77%) enrolled in patient empowerment program Haimen City Publications (2016) Cohen, C, Evans AA, Huang P, London WT, Block JM, Chen G. Hepatitis B knowledge among key stakeholders in Haimen City, China: Implications for addressing chronic HBV infection. (Hepatology, Medicine and Policy)  (2015) Evans AA, Cohen C, Huang P, Qian L, London WT, Block JM, Chen G. Prevention of perinatal hepatitis B transmission in Haimen City, China: Results of a community public health initiative. (Vaccine)  (2014) Chen G, Block JM, Evans AA, Huang P, Cohen C. Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China. (BMC Public Health)    Ho Chi Minh City, Vietnam Based on the model of success the HBF has developed in Haimen City, China, we have been asked to join the Vietnam Viral Hepatitis Alliance to address the enormous burden of hepatitis B. Vietnam is located in Southeast Asia where chronic hepatitis B infections are estimated to range between 8-25% of the population. Ho Chi Minh City (formerly known as ‘Saigon’) is located in South Vietnam and has a population of approximately 10 million people. It will be the site of an ambitious public health campaign around hepatitis B that is supported by the local government and public health officials in the city. The official launch of this international initiative is on World Hepatitis Day – July 28, 2016. Learn more about the Vietnam Viral Hepatitis Alliance.   1st World Hepatitis Summit in 2015 The HBF is proud to have been invited to speak and participate in the 2015 World Hepatitis Summit sponsored by the World Health Organization (WHO), in partnership with the Scottish Government and the World Hepatitis Alliance. It was held in Glasgow, Scotland on Sept. 2-4, 2015 with more than 80 countries represented. The WHO invited 600 leaders from government, public health agencies, non-governmental organizations to attend this historic meeting. The message was serious. Hepatitis B and C kill more people each year than HIV/AIDS and tuberculosis, and combined represent the 7thleading cause of death worldwide. Without significant intervention, WHO estimates there will be 20 million needless deaths over the next 15 years. WHO leaders unveiled their first-ever global viral hepatitis plan, the first of its kind. Its twin goals of reducing chronic viral hepatitis cases by 90 percent and deaths by 65 percent by 2030 are ambitious, but possible.

  https://www.hepb.org/research-and-programs/public-health-programs/
• Coalition Against Hepatitis for People of African Origin (CHIPO)

  The Coalition Against Hepatitis for People of African Origin (CHIPO) is a community coalition co-founded and led by the Hepatitis B Foundation. We are comprised of organizations and individuals interested in addressing the high rates of hepatitis B infection among African communities around the world. CHIPO serves as a forum for sharing information and best practices, and improving national capacity to improve hepatitis B awareness, testing, vaccination and treatment among highly affected African communities. People of African origin are disproportionately affected by hepatitis B infection. In fact, in some African communities in the U.S., between 5% and 15% of people have chronic HBV infection. Unfortunately, due to the silent nature of the disease, lack of disease awareness, and limited health care access, most African community members who have hepatitis B DO NOT KNOW that they are infected. This puts them at much greater risk for premature death from cirrhosis or liver cancer. The key to addressing the high burden of hepatitis B infection in people of African origin is to improve awareness and access to hepatitis B information, screening, vaccination, and follow-up care. CHIPO brings together people from around the world who are working in their own local communities to address these very issues.   Join CHIPO! Does your organization serve African populations, or are you a passionate community member? All are welcome at CHIPO's coalition calls! Our next call will take place on Monday July 17th, 2023 at 3pm Eastern Time. Email beatrice.zovich@hepb.org if you have questions or are interested in joining!  Watch our webinar! Hepatitis B and HIV Screening, Prevention, and Management for African Immigrants and Refugees in the United States: Barriers and Solutions [embed width="700" height="395" class="leftAlone" thumbnail="https://i.ytimg.com/vi/AG0kCk-FVw8/hqdefault.jpg?r"]http://www.youtube.com/watch?v=AG0kCk-FVw8&ab_channel=HepatitisBFoundation[/embed] If you missed our webinar on May 17th, watch the recording to hear from a diverse panel of experts who will share insights about the unique challenges faced by the African immigrant and refugee community in accessing appropriate diagnosis and care for hepatitis B and HIV in the United States and will discuss the latest strategies for reducing the spread of hepatitis B and HIV and addressing the epidemics in a holistic way. Listen to a new podcast: Spotlight on Stigma Join us for a podcast in which researchers from the Hepatitis B Foundation in the United States and the University of New South Wales in Australia come together to discuss the profound impacts stigma can have on the lives of people living with hepatitis B. Click here to listen! News and Updates Check out our blog post, which provides an overview of CHIPO's goals and objectives, where we've been and where we're going. We hope you join us! [embed width="335" height="251" class="leftAlone" thumbnail="https://i.ytimg.com/vi/oXSEaQANvVE/hqdefault.jpg?r"]http://youtu.be/oXSEaQANvVE[/embed] Check out a recent webinar collaboration between CHIPO & Hep B United: Addressing Myths & Misconceptions about Hepatitis B among African Immigrant Communities around the United States. There are many myths surrounding various aspects of hepatitis B, including its prevalence, transmission, prevention, testing, severity, and treatment. This webinar explores some of the most widespread misconceptions, particularly in African communities around the United States, from a variety of perspectives, including those of healthcare providers and a community health practitioner. Watch to learn more! Recent article (May 2023): Viral hepatitis like AIDS: that’s why we need to eliminate them (and we can’t) Recent article (May 2023): High hopes but low pledges for hepatitis conference in Geneva Recent article (April 2023): Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale Recent article (April 2023): Opinion: Here’s why Gavi must start hepatitis B vaccination in Africa Recent article (April 2023): No racial disparities observed in chronic HBV treatment rates among eligible patients Recent article (April 2023): Mapping hepatitis B virus genotypes on the African continent from 1997 to 2021: a systematic review with meta-analysis Recent article (March 2023): Research uncovers cheaper diagnostic tools for chronic hepatitis B in Africa Recent Scientific Reports article (February 2023): The development of a machine learning algorithm for early detection of viral hepatitis B infection in Nigerian patients Recent Lancet article (February 2023): Global reporting of progress towards elimination of hepatitis B and hepatitis C Recent Nature Communications article (January 2023): Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa Recent Mirage article (January 2023): Simpler Tests Needed for Africa’s Chronic Hep B Patients Recent Journal of Gastroenterology article (September 2022): Prevalence and Predictors of Viral Hepatitis D Co-Infection in Chronic HbsAg Carriers View our Publication! Barriers to Hepatitis B Screening and Prevention for African Immigrant Populations in the United States: A Qualitative Study (2020) Exciting news about National African Immigrant and Refugee HIV/AIDS & Hepatitis Awareness (NAIRHHA) Day!: Reps. Johnson, Meng, and Lee Push to Recognize Sept. 9th as National African Immigrant and Refugee HIV/AIDS and Hepatitis Awareness (NAIRHHA) Day From our Partners The April 2023 CHIPO coalition call focused on advocacy efforts in different contexts and featured a presentation by Dr. Gilbert Ngwaneh Miki, Executive Director and Founding President of Community Vision Group in Cameroon and Malawi, about the current initiatives of his organization in the fight to eliminate hepatitis B. You can view these slides here. We also welcomed Frank Hood, Associate Director of Policy and Partnerships at the Hepatitis B Foundation and Director of Hep B United, as well as Rhea Racho, Director of Advocacy and Engagement at the Hepatitis B Foundation, to share about the current advocacy priorities and profile of the Hepatitis B Foundation. You can view these slides here.  The March 2023 CHIPO coalition call included a presentation from Abby Showalter, Senior Manager of Social Media and Communications at the Hepatitis B Foundation, about how to use social media effectively as a public health tool. You can view Abby's slides here. The November 2022 CHIPO coalition call featured a presentation by Dr. Yasmin Ibrahim of the Hepatitis B Foundation, who presented her recent paper entitled Attitudes towards clinical trial participation among people living with chronic hepatitis B. You can view Dr. Ibrahim's slides here. Check out a new podcast from our partners at the United States Coalition for African Immigrant Health, all about hepatitis B in African communities, and featuring two of our new #justB storytellers! In July of 2022, the CHIPO coalition call focused on stigma and discrimination surrounding hepatitis B in African communities and included presentations from Mohamed Ali, a Public Health Manager for Seattle and King County, Washington and Cait O'Donnell, Manager of Health and Social Programs at African Family Health Organization (AFAHO) in Philadelphia. You can view Mohamed's slides here and Cait's slides here. CHIPO's May 2022 coalition call featured an overview of the fundamentals of grant-writing. View slides from this presentation here.  At our March 2022 meeting, we hosted Dr. Yvonne Nartey of the Cape Coast Teaching Hospital in Ghana and Mr. Kenneth Kabagambe, Founder and Executive Director of the National Organization for People Living with Hepatitis B in Uganda. Both discussed the great hepatitis B and C advocacy efforts they are undertaking in their respective countries. You can view Dr. Nartey's slides here.  On our February 2022 coalition call, we were pleased to host Fatima Omarufilo, Program Coordinator and Patient Navigator at the Starfish Program at Montefiore Medical Center in the Bronx, NY, who presented the work that she and her colleagues had done on their paper about breaking down barriers for hepatitis B screening in the Bronx West African community through education in collaboration with faith-based organizations. You can view Fatima's slides here.  Montefiore Einstein Starfish Project is offering FREE hepatitis B testing for West Africans in the Bronx, NYC. Click here for more details. The Starfish Program has hepatitis B fact sheets available for West African communities that can be found in English, Twi, Hausa, French, and Igbo. African Services Committee in New York City created a flyer in both English and French about understanding your hepatitis B test results. View this resource here. From our Blog CHIPO Partner Highlight: Hepatitis B Initiative of Washington, D.C. What's the Difference?: Herbal Remedies and Supplements v. Western Medicine Reactivation with Hepatitis B: Understanding Risk Factors and Prevention Strategies CHIPO Partner Highlight: United States Coalition for African Immigrant Health CHIPO Partner Highlight: Illinois Public Health Association CHIPO Partner Highlight: Great Lakes Peace Centre Happy NAIRHHA Day 2021! Tackling Hepatitis B in Africa: The First Nigerian Hepatitis Summit Where is Hepatitis Delta? High Prevalence of Hepatitis B/Delta Coinfection in Central Africa Raising Awareness about Hepatitis B in African Immigrant Communities in the US CHIPO Call Minutes April 2023 March 2023 January 2023 November 2022 July 2022 May 2022 March 2022 February 2022 December 2021 November 2021 July 2021 January 2021 November 2020 July 2020 May 2020 January 2020  Social Media       

  https://www.hepb.org/research-and-programs/chipo/
• Hep B Press Releases

  The Hepatitis B Foundation is happy to assist the media in reporting on the impact of hepatitis B worldwide. We can coordinate interviews with experts in research, public health, community outreach efforts and immunization and treatment initiatives. News media contact: Ed Tate, director, communications & marketing, edward.tate@hepb.org, 267-934-3475   Gala puts the spotlight on creating family and support for those living with hepatitis B The Hepatitis B Foundation Annual Gala honored two global leaders in the fight to advance hepatitis B science, prevention and treatment. The Foundation held its annual Gala, a fundraiser that celebrates the nonprofit’s people and achievements, on March 10 at The Warrington, a popular venue in Warrington, Pa. Read more here.  Global leader, New Jersey physician treating people living with hepatitis B takes new role with Hepatitis B Foundation Su Wang, MD, MPH, FACP, a prominent leader in the global hepatitis community and a member the Hepatitis B Foundation’s Board of Directors, has become the Foundation’s first Senior Advisor for Global Health. Please read more here. Hepatitis B Foundation releases white paper calling health care providers into action following new hepatitis B screening and vaccination recommendations  With the U.S. Centers for Disease Control and Prevention (CDC) release last week of new guidance for hepatitis B screening, adding to updated recommendations on vaccination that the CDC put out last spring, the Hepatitis B Foundation has produced a white paper with guidance on how health care providers in the U.S. can begin implementing these new universal hepatitis B screening and vaccination (for adults ages 19-59) guidelines. Please read more here. New CDC Universal Screening Recommendations will save lives, Hepatitis B Foundation President Dr. Chari Cohen says New guidance released today by the U.S. Centers for Disease Control and Prevention (CDC) that recommend testing of all adults ages 18 and older will save lives, ultimately, says Hepatitis B Foundation President Chari A. Cohen, DrPH, MPH. Read more here.  Louis P. Kassa III, CEO of the Hepatitis B Foundation, Blumberg Institute and Pennsylvania Biotechnology Center named to Philadelphia’s Power 101 Louis P. Kassa III, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC) was chosen by the Philadelphia Business Journal for its Power 101 list, which is being released this week. Read more here. Hepatitis B Foundation president responds to Janssen decision on the company’s hepatitis B drug development program The Johnson & Johnson subsidiary is ending efforts produce a treatment for hepatitis B, a life-threatening infection that impacts 300 million people worldwide. Hepatitis B Foundation President Chari A. Cohen, DrPH, MPH, today expressed frustration that Janssen has decided to shutdown its program to develop a drug to treat hepatitis B, which is incurable and infects millions in the U.S. and globally. Read more here. Globally prominent advocate and physician chosen for Hepatitis B Foundation’s 2023 Community Commitment Award The Hepatitis B Foundation, a global nonprofit organization based in Doylestown, Pa., has chosen Su Wang, MD, MPH, FACP, dedicated physician and advocate, to receive the Foundation’s 2023 Community Commitment Award. Read more here.  Dr. Yasmin Ibrahim appointed to national Patient Engagement Collaborative The U.S. Food and Drug Administration and the Clinical Trials Transformation Initiative (CTTI) has announced eight newly selected representatives for the Patient Engagement Collaborative, including Yasmin Ibrahim, MD, PhD, MBA, of the Hepatitis B Foundation. Read more here.  Comprehensive hepatitis B program in Vietnam provides an excellent model for other countries A comprehensive program in Vietnam connected to Johns Hopkins University that we support is developing a highly effect model for eliminating hepatitis B in a hig-prevalence area. Please read more here. Open letter to Gavi urging them to start their hepatitis B birth dose campaign  The Hepatitis B Foundation has signed on to an open letter to Gavi, the Vaccine Alliance, urging them to start their hepatitis B birth dose campaign. Read the open letter in The Lancet here.  Hepatitis B Foundation announces third series of continuing education series on hepatitis B for health care providers and public health professionals The Hepatitis B Foundation launched Hep B Project ECHO in 2021, and the program is now gearing up for a third series. This free CME continuing education series for health care providers and public health professionals uses the ECHO Model™ to deliver educational content about hepatitis B to physicians, nurses, pharmacists, public health coordinators, medical students/fellows and other health care professionals. Read more here.  Hepatitis B Foundation hails decision by U.S. Public Health Service Corps to accept future applicants living with chronic hepatitis B infection and HIV The Hepatitis B Foundation applauds the decision of the U.S. Public Health Service Commissioned Corps to accept future applicants living with chronic hepatitis B infection and HIV. The USPHS Commissioned Corps announced the change yesterday (Dec. 1), which was World AIDS Day. Previously, HIV and hepatitis B infection were both considered disqualifying medical conditions. This new decision reflects the latest scientific evidence and opens the door for applicants with hepatitis B and HIV to serve as uniformed Public Health Service officers. Read more here.  German scientist, inventor of world’s first treatment for hepatitis D, to receive the 2023 Baruch S. Blumberg Prize The Hepatitis B Foundation, a global nonprofit organization, today announced that Stephan Urban, PhD, distinguished professor and globally recognized virologist, has been chosen to receive its 2023 Baruch S. Blumberg Prize. Read more here.  Researchers and people living with hepatitis B meet in Paris at the third Hepatitis B Community Forum The perspectives of the almost 300 million people living with hepatitis B is critical as scientists and clinicians continue working toward hepatitis B cure and elimination, which was the focus of a special session that concluded the 2022 International HBV Meeting. Read more here.  Hepatitis B Foundation mourns Bill Mason, an accomplished scientist whose discovery led to current treatments for hepatitis B The Hepatitis B Foundation mourns the loss of William S. Mason, PhD, an internationally influential scientist dedicated to the study of hepatitis B and longtime friend of the Hepatitis B Foundation, who passed away Sept. 19. Read more here. Hepatitis B Foundation raises alarm about findings from new federal viral hepatitis surveillance report A new CDC report shows major COVID-related disruptions in hepatitis B testing and significant health equity concerns about the virus’ impact on the Asian American/Pacific Islander community. Read more here.  Hepatitis B Foundation strongly supports Congressional letters urging Biden administration to end discriminatory military policy The Hepatitis B Foundation, which has long fought against discrimination of people living with hepatitis B, strongly supports a new effort to permit individuals with hepatitis B or HIV to serve in the U.S. military. Please read more here. Report from Washington: Hepatitis B Foundation Requested Language Included in FY2023 House and Senate Appropriation Reports The Hepatitis B Foundation’s policy team spends considerable time and effort each year to increase federal prioritization and advocate for funding for hepatitis B and liver cancer research and public health programming. Please read the full report here. Two Global Community Advisory Boards launched by the Hepatitis B Foundation To further its work as the world’s leading nonprofit dedicated to hepatitis B and liver cancer, the Hepatitis B Foundation has formed two new Global Community Advisory Boards. At the Foundation’s invitation, 81 people worldwide, primarily people living with hepatitis B and delta infections, applied to serve on the advisory boards. Please read more here. Longtime Board Chair honored by his colleagues  The Hepatitis B Foundation's Board of Directors and leadership recognized Joel D. Rosen, Esq., at the board's recent meeting for his nearly two decades of service. A board member since 2003, he was chair of the board from 2009 until stepping down last month. Read more here.  Dr. Chari A. Cohen becomes president of the Hepatitis B Foundation Chari A. Cohen, DrPH, MPH, today (July 1) became president of the Hepatitis B Foundation, a global nonprofit organization based in Doylestown, Pa. Timothy M. Block, PhD, founding president of the organization, is now executive chair of the Foundation's Board of Directors. Please read more here. Department of Health Highlights the Importance of Viral Hepatitis Awareness, Need for Expansion of Syringe Services The Pennsylvania Department of Health joined advocates and residents with lived experiences to highlight the importance of viral hepatitis awareness along with the success of syringe services programs. Read this Pennsylvania Pressroom release here.  Hepatitis B Foundation, StoryCenter release new #justB stories from people with lived experience For Hepatitis Awareness Month, the Hepatitis B Foundation has released five new videos as part of its national #justB storytelling campaign, which conveys the powerful stories of real people affected by hepatitis B. Read more here.  Hepatitis outbreaks among children in the U.S. and Europe Pediatric hepatitis outbreaks in the U.S, and several European countries over the past few weeks and months have raised new concerns as a number of children have suffered liver damage (liver inflammation, or “hepatitis”) after becoming ill. Please read more here. Philadelphia City Council recognizes May as Hepatitis Awareness Month The Hepatitis B Foundation and Hep B United Philadelphia applaud the City of Philadelphia’s Resolution that recognizes May as Hepatitis Awareness Month. Please read more here. Hepatitis B Foundation hosts Princeton Workshop on Liver Cancer The Hepatitis B Foundation hosted more than 30 top scientists and physicians from across the U.S. for a day-long meeting April 28 on "Liver Cancer Risk, Prevention and Early Detection: Challenges and Opportunities to Improve Outcomes." Please read more here.  Annual Gala raises a record amount for the local Hepatitis B Foundation Doylestown, Pa., April 27, 2022 – The Hepatitis B Foundation Gala, an annual fundraiser and celebration of the nonprofit’s people and achievements, was held on April 1 at The Warrington, a popular event venue in Warrington, Pa. Gilead Sciences Inc. was the presenting sponsor of this record-breaking event. Read more here.  Hepatitis D Roundtable to Address Unmet Needs of Patients Fairfield, NJ—April 21, 2022—The American Liver Foundation (ALF) and Hepatitis B Foundation will join forces with key stakeholders concerned with identifying and addressing the unmet needs of people living with hepatitis D virus (HDV). Read more here.  DiRx partners with Hepatitis B Foundation to offer low-cost medications East Brunswick, New Jersey, April 14, 2022 - Hepatitis B Foundation, a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B, is the newest partner of DiRx, a fast-growing digital pharmacy platform focused on generic medicine access and affordability. Hepatitis B is the most common serious liver infection in the world, and a 2021 study estimated that as many as 2.4 million people in the U.S. live with hepatitis B. Please read more here.  Many more U.S. adults to get vaccinated against hepatitis B following move by CDC Doylestown, Pa., April 1, 2022 – The Hepatitis B Foundation enthusiastically endorses the adoption of new adult vaccination guidelines for hepatitis B by the U.S. Centers for Disease Control and Prevention (CDC), and the Foundation is organizing a group of experts to help with implementation to ensure millions more U.S. adults get vaccinated against the dangerous virus. Please read more here. Hepatitis B Foundation receives Congressional funding for a Center of Public Health Excellence Doylestown, Pa., March 14, 2022 – With the passage of the Fiscal Year 2022 Omnibus Appropriations Act, the Hepatitis B Foundation will receive $475,000 to create a Center of Public Health Excellence focused on hepatitis B elimination by providing expert resources, advice, training, capacity building and technical assistance for state and local partners including health departments, social service organizations, and community-based health providers on how to best prevent, treat and control hepatitis B and to increase the rate of adult vaccination and testing for hepatitis B. Read more here.  CTC Foundation of Princeton donating $100,000 to Hepatitis B Foundation  Doylestown, Pa., Feb. 3, 2022 – The CTC Foundation of Princeton, N.J., is donating $100,000 over five years to the Hepatitis B Foundation, a global nonprofit organization that is engaged in advocacy, education and research to combat hepatitis B, the most common serious liver infection in the world. Read more here.  Hepatitis B Foundation senior vice president and board member speak on popular podcast Doylestown, Pa., Jan. 27, 2022 – A leading science podcast currently is focusing on hepatitis B, and the two experts interviewed are Chari Cohen, DrPH, MPH, senior vice president of the Hepatitis B Foundation, and Su Wang, MD, MPH, FACP, a member of the Foundation’s Scientific and Medical Advisory Board and its Board of Directors. Read more here.  Anonymous donor provides record gift for hepatitis B research Doylestown, Pa., Jan. 12, 2022 – A very generous Florida couple who wishes to remain anonymous has contributed $500,000 to the Baruch S. Blumberg Institute, the research arm of the Hepatitis B Foundation, to advance research toward a cure for hepatitis B, the most common serious liver infection in the world. Read more here.  Two hepatitis B medications available free through Hepatitis B Foundation and Rx Outreach partnership St. Louis, Dec. 6, 2021 — Two national nonprofit organizations have announced a new venture to provide two of the most commonly prescribed medications for chronic hepatitis B at no cost to people in need. Hundreds of people across the country are expected to benefit from the program. Read more here.     Canadian scientist chosen for the 2022 Hepatitis B Foundation’s Blumberg Prize Doylestown, Pa., Nov. 22, 2021 – The Hepatitis B Foundation, a global nonprofit organization, today announced that D. Lorne Tyrrell, MD, PhD, Distinguished University Professor in the Department of Medical Microbiology and Immunology and the University of Alberta, has been chosen as the recipient of its 2022 Baruch S. Blumberg Prize for outstanding contributions to advance the science and medicine of hepatitis B. Read more here.  Doylestown native creates Sunrise Educational Fund to support high school and college students enrolled in Blumberg Institute programs Doylestown, Pa., Nov. 8, 2021 – Baruch S. Blumberg Institute President Timothy M. Block today announced the establishment of The Sunrise Educational Fund, an endowment to support the Institute’s academic and experiential learning programs for high school and college students. Read more here.  Landmark vote by CDC’s Advisory Committee on Immunization Practices (ACIP) to recommend universal hepatitis B vaccination Doylestown, Pa., Nov. 4, 2021 - The Hepatitis B Foundation applauds yesterday’s landmark vote by the Advisory Committee on Immunization Practices (ACIP) to recommend universal hepatitis B vaccination for all adults ages 19 to 59 in the U.S. Read more here.  Hepatitis B Foundation strongly endorses the Liver Illness Visibility, Education and Research (LIVER) Act of 2021 Oct. 22, 2021 – Introduced in the U.S. Senate (S.3041) by Sen. Tammy Duckworth (D-IL) and in the House (H.R.5675) by Rep. Nydia Velazquez (D-NY), the bill takes bold steps to increase investments in research, prevention and awareness activities to address hepatitis B, which kills an estimate 820,000 annually, and to address liver cancer, which continues to grow in incidence and is the second deadliest cancer. Read more here. Hepatitis B Foundation Board of Directors selects Dr. Chari Cohen to succeed Dr. Timothy Block as president Sept. 27, 2021 – The Hepatitis B Foundation, a global nonprofit organization based in Doylestown, Pa., today announced that Chari Cohen, DrPH, MPH, senior vice president, will become president of the Foundation, effective July 2022. Read more here.  New president announced for the Pennsylvania Biotechnology Center (PABC) Sept. 27, 2021 – Louis P.  Kassa, executive vice president and chief operating officer of the nonprofit Pennsylvania Biotechnology Center (PABC), will become the center’s president in July 2022. Read more here. Major successes on Capitol Hill Aug. 26, 2021 – A key aspect of the Hepatitis B Foundation’s efforts to eradicating hepatitis B is advocacy, particularly trying to educate and influence members of the U.S. Congress and their staffs. Please read more here. CDC awards $1.375 million, 5-year grant to Hepatitis B Foundation for expansion of Hep B United Aug. 13, 2021 – The U.S. Centers for Disease Control and Prevention has awarded a $1.375 million, five-year grant to the Hepatitis B Foundation to continue leading and expanding Hep B United, a nationwide coalition that operates in collaboration with the Association of Asian Pacific Community Health Organizations. Please read more here. Hepatitis B Foundation Members Selected to Participate as Consumer Reviewers in the Congressionally Directed Medical Research Program’s Peer Reviewed Medical Research Program for the U.S. Department of Defense Aug. 2, 2021 – The Congressionally Directed Medical Research Program’s (CDMRP), Peer Reviewed Medical Research Program (PRMRP) for the U.S. Department of Defense has selected consumer advocates nominated by the Hepatitis B Foundation. Please read more here.  Hepatitis B Foundation launches first global registry of discrimination against people living with hepatitis B May 13, 2021 – People globally who are living with hepatitis B often experience discrimination in variety of ways, including denial of access to employment and education, even in the U.S., and an American nonprofit organization has launched the world’s first initiative to track and analyze that discrimination. Please read more here. Hepatitis B Foundation supports launch of new global online forum dedicated to supporting people with hepatitis B, connecting with health experts April 13, 2021 – The Hepatitis B Foundation is pleased to support the official launch of HepBcommunity.org, a new global online forum dedicated to supporting those living with and affected by hepatitis B. Please read more here. Hepatitis B Foundation to hold its annual Crystal Ball Gala on April 30 April 8, 2021 – Our annual Crystal Ball Gala later this month holds a special significance: it is the ceremonial start of the Foundation's 30th Anniversary celebration. Please read more here. Hepatitis B Foundation mourns the passing of John C. Martin, pharmaceutical industry leader  April 1, 2021 - The leadership and staff of the Hepatitis B Foundation share a high regard for John C. Martin, PhD, former CEO of Gilead Sciences Inc., who died suddenly this week. Please read more here. Chronic hepatitis B is far more prevalent among U.S. residents than previously reported March 10, 2021 – The number of adults living in the U.S. who have chronic hepatitis B infection may be as high as 2.4 million, which is nearly three times greater than the federal government’s official estimate, according to a new analysis by a team of public health experts, scientists and physicians. Please read more here. Hepatitis B Foundation mourns loss of co-founder Paul Witte Feb. 15, 2021 The Hepatitis B Foundation announces with great sadness the passing of Mr. Paul Witte, 94. An award-winning industrial and product-design engineer, Paul never hesitated to share his talents and resources to help create the Foundation as an important advisor and generous philanthropist. Please read more here. All of Us research program  Feb. 15, 2021 – From 2020-2021, the proportion of Asian American and Pacific Islander communities represented in biomedical research has doubled, growing from 2% to 4%. The All of Us Research Program wants to encourage this valuable trend going. Please read more here. Hepatitis B Foundation launches continuing education series on hepatitis B for health care providers and public health professionals  Feb. 5, 2021 – The Hepatitis B Foundation has launched Hep B Project ECHO Philadelphia, a continuing education series for health care providers and public health professionals using the ECHO Model™ to deliver educational content about hepatitis B to physicians, nurses, pharmacists, public health coordinators and other health care professionals. Please read more here. Hepatitis B Foundation applauds release of National Hepatitis Strategic Plan Jan. 7, 2021 – Today the U.S. Department of Health and Human Services (HHS) released the Viral Hepatitis National Strategic Plan, which provides a roadmap toward the elimination of viral hepatitis in the U.S. (2021-2025), including key objectives and strategies to eliminate hepatitis B and related health inequities. Please read more here. Bristol Myers Squibb provides grant for work to reduce disparities in liver cancer for high-risk minority groups in the U.S. Dec. 22, 2020 – Bristol Myers Squibb has awarded a one-year, $134,000 grant to the Hepatitis B Foundation to close the disparity gaps related to hepatitis B-associated liver cancer in the United States among Asian Americans, Pacific Islanders, African immigrant communities and other high-risk groups. Please read more here. Federal Task Force Recommendation for Hepatitis B Screening Fails to Close Gaps in Diagnosis Rates Dec. 16, 2020 – The Hepatitis B Foundation today released the following statement regarding the recent publication of a new statement from the U.S. Preventive Services Task Force (USPSTF). Please read more here. Hepatitis B community leaders convene to address eliminating hepatitis B during COVID-19 pandemic Nov. 30, 2020 – Hep B United, a national coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO) to address the silent epidemic of hepatitis B, will host its eighth annual (and first virtual) summit Dec. 2-4. Please read more here. Hep B United to honor Corinna Dan, former HHS official Hep B United and the HBV Forum are pleased to name Corinna Dan, RN, MPH, as the 2020 recipient of the Hepatitis B Federal Champion Award for her commitment to eliminating hepatitis B. Ms. Dan will receive the award at the Hep B United Virtual Summit on Dec. 4. Please read more here. Hepatitis B Foundation announces 2021 Baruch S. Blumberg Prize Nov. 12, 2020 -- The Hepatitis B Foundation is announcing today (Nov. 12) that Wenhui Li, Ph.D., has been chosen as the recipient of its 2021 Baruch S. Blumberg Prize for outstanding contributions to advance the science and medicine of hepatitis B. Please read more here. Hepatitis B Foundation applaud HHS letter on discrimination against people living with hepatitis B pursing careers in health care  Nov. 6, 2020 - The Hepatitis B Foundation applauds the U.S. Department of Health and Human Services (HHS) for issuing a letter to health professions schools in the U.S., calling for renewed attention to admissions and clinical placement policies and their obligation to comply with federal civil rights laws that protect the rights of people living with hepatitis B. Please read more here. Major new award to be presented to our co-founders Joan and Timothy Block Nov. 4, 2020 - Hepatitis B Foundation co-founders Joan Block, R.N., and Timothy M. Block, Ph.D., will be receiving a very significant honor in November during The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. The Association recently announced that, during the Nov. 13-16 Liver Meeting Digital Experience, the Blocks will receive the inaugural Distinguished Advocacy Service Award. Please read more here. Hepatitis B Foundation launches new tool to assist people living with hepatitis B in making decisions on health insurance Oct. 29, 2020 - The Hepatitis B Foundation today released a new report, Health Insurance Costs Impacting Shoppers Living with Hepatitis B, that is designed to help those living with chronic hepatitis B and their caregivers make better-informed decisions when choosing health insurance plans. Please read more here. Hepatitis B Foundation releases report on first-ever Externally Led Patient-Focused Drug Development meeting for hepatitis B Oct. 27, 2020 - In cooperation with the U.S. Food and Drug Administration (FDA), the Hepatitis B Foundation hosted an Externally Led Patient-Focused Drug Development (PFDD) meeting focused on hepatitis B on June 9, 2020. Today, the Foundation released its comprehensive report on the information-gathering event. Please read more here. Hepatitis B Foundation launches B the Voice Story Bank  Aug. 18, 2020 – The Hepatitis B Foundation today is launching its new B the Voice Story Bank, an initiative to gather the stories of people around the world affected by hepatitis B. Please read more here. Hepatitis B Foundation expresses appreciation for the work of Dr. Ding-Shinn Chen with the announcement of his death June 25, 2020 - The Hepatitis B Foundation today is expressing its profound sadness at the passing of Dr. Ding-Shinn Chen, distinguished professor of the National Taiwan University College of Medicine. Please read more here. Hepatitis B Foundation and Hep B United Statement on the Federal Government’s Rollback of Critical Health Care Protections  June 16, 2020: The U.S. Department of Health and Human Services (HHS) finalized a rule last week to roll back critical nondiscrimination protections provided under Section 1557 of the Affordable Care Act (ACA). Please read more here. Two Powerful Editorial Published by the Hepatitis B Foundation  May 30, 2020: Two Powerful Editorial Published by the Hepatitis B Foundation. Please read them here. HBF to host first-ever online Externally Led Patient-Focused Drug Development meeting May 28, 2020: In cooperation with the FDA, the Hepatitis B Foundation will host an online Externally Led Patient-Focused Drug Development meeting for those living with hepatitis B and other key stakeholders on June 9 from 12:30-4:30 p.m. EDT. Please read more here.  Leading the way to 2030 May 27, 2020: "Leading the Way to 2030" is the theme of our recently released 2019 Annual Report. Please take a few minutes to review the report, posted here. Rhea Racho named as a Health Hero! May 15, 2020: Congratulations to Rhea Racho, Hepatitis B Foundation public policy and program manager, who has been named an AANHPI Health Hero by AAPCHO! Please read more here. Hepatitis B Foundation Expands Hepatitis B Prevention Policy Initiatives May 6, 2020: The Hepatitis B Foundation has launched a new Hepatitis B Prevention Policy Program aimed at increasing adult hepatitis B vaccination rates in the U.S. The program will build and expand the Foundation’s policy and advocacy initiatives and increase engagement with federal and state public health agency partners to improve hepatitis B prevention and vaccination infrastructure and strategies. Please read more here. HHBV Vaccinations Save Lives, Reduce New Infections: National Adult Hepatitis B Vaccination Awareness Day April 30, 2020: Only one quarter of U.S. adults ages 19 and older are fully vaccinated against hepatitis B, despite the availability of a safe and effective vaccine for more than 30 years. Today, on National Adult Hepatitis B Vaccination Awareness Day, we are calling for an increased commitment to improving adult hepatitis B vaccination coverage in the United States to reduce the number of new hepatitis B infections and hepatitis B-related deaths. Please read more here.  Hepatitis B Foundation Says "Thank You!" to its 100-plus Volunteers April 22, 2020: During National Volunteer Week in the United States, the Hepatitis B Foundation is publicly thanking its more than 100 volunteers worldwide. Those dedicated individuals work with the Foundation to help serve people living with hepatitis B, their families and health care providers, sharing information about the resources available to them, particularly about the treatment and prevention of the infectious disease. Please read more here. Hepatitis B Foundation Announces Annual Fundraising Event to Go Virtual April 24 April 8, 2020: In this challenging time, the Hepatitis B Foundation continues to serve people living with hepatitis B, their families and health care providers, and planning continues for its principal annual fundraiser. The foundation is adapting its 2020 Crystal Ball Gala from an in-person event to our first “Pajama Gala.” Please read more here. Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center Announce New Director of Communications and Marketing April 8, 2020: The Hepatitis B Foundation recently appointed Edward F. Tate III, a Newtown resident, as director of communications and marketing. Along with leading the foundation’s communications and marketing, Tate also will handle those functions for the Baruch S. Blumberg Institute and the Pennsylvania Biotechnology Center (PABC). Please read more here. Hepatitis B Foundation Strongly Supports the Strategic Plan for Trans‐NIH Research to Cure Hepatitis B Dec. 11, 2019: The National Institutes of Health (NIH) released a groundbreaking Strategic Plan for Trans‐NIH Research to Cure Hepatitis B on Dec. 10. This Plan is the first product from the NIH Hepatitis B Cure Strategic Plan Working Group that was created as a result of Fiscal Year 2019 Congressional Appropriations Report language advocated for by the Hepatitis B Foundation. Please read more here. Hepatitis B Foundation Announces 2020 Baruch S. Blumberg Prize Winner Nov. 18, 2019: The Hepatitis B Foundation has named John Taylor, PhD, the recipient of its 2020 Baruch S. Blumberg Prize for excellence in hepatitis B research. Dr. Taylor is a Professor Emeritus at Fox Chase Cancer Center in Philadelphia. Please read more. Hepatitis B Foundation Plans Externally-Led Patient-Focused Drug Development Meeting for Chronic Hepatitis B in June 2020 Nov. 6, 2019: The Hepatitis B Foundation is pleased to have been approved by the U.S. Food and Drug Administration (FDA) to host an externally-led Patient-Focused Drug Development (PFDD) meeting on June 9, 2020 that will focus on chronic hepatitis B infection (CHB). Read more. U.S. Falls Short in Reaching 2020 Goals for Hepatitis B Sept. 18, 2019: The U.S. is falling short of targets for hepatitis B vaccination, and for reducing new hepatitis B cases, according to the 2019 National Viral Hepatitis Progress Report, released this week by the Centers for Disease Control and Prevention (CDC). Read more. Hepatitis B Foundation Calls for Increased Resources for Hepatitis B Prevention in Response to CDC 2017 Surveillance Data Report Sept. 11, 2019: The Hepatitis B Foundation is calling for increased resources to improve hepatitis B vaccination rates and educate high-risk communities, in response to newly-released viral hepatitis surveillance data from the Centers for Disease Control and Prevention (CDC). Read more. Our Voices Made a Difference: CVS Caremark to Cover Vemlidy Prescriptions Sept. 9, 2019: The Hepatitis B Foundation, along with our network of patients, providers and partners, has successfully advocated for improved access to the hepatitis B medication Vemlidy in the US. Read more. Hepatitis B Foundation Commends New Rx Outreach Program to Provide Access to Affordable Hepatitis B Medication The Hepatitis B Foundation commends  Rx Outreach, a nonprofit online pharmacy, for expanding their service to provide medications to help more than 2 million Americans who are chronically infected with hepatitis B. Read more.  Hepatitis B Foundation Endorses the Liver Illness Visibility, Education, and Research (LIVER) Act of 2019 The Hepatitis B Foundation (HBF) strongly endorses yesterday’s re-introduction of the Liver Illness Visibility, Education and Research (LIVER) Act of 2019 (HR 3016). Read more.   2018 Press Releases Hepatitis B Foundation Announces 2019 Baruch S. Blumberg Prize Winner The Hepatitis B Foundation has named Christoph Seeger, PhD, the recipient of its 2019 Baruch S. Blumberg Prize for excellence in hepatitis B research. Dr. Seeger will receive his award at the 2019 Crystal Ball Gala on April 26, 2019. Read more. Hep B United Applauds Bipartisan Legislation to Combat Opioid Crisis and Opioid Related Infectious Diseases Hep B United today released the following statement, commending Congress for working together to pass the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. The legislation was signed into law by the president, following overwhelming bipartisan Congressional support. Read more Hepatitis B Foundation Endorses the Liver Illness Visibility, Education, and Research (LIVER) Act of 2018 The Hepatitis B Foundation (HBF) strongly endorses the introduction the Liver Illness Visibility, Education and Research (LIVER) Act of 2018. Introduced by Representative Nydia Velazquez (D-NY), the bill takes bold steps to increase investments in research, prevention, and awareness activities to address hepatitis B. Read more. Hepatitis B Foundation Calls for Universal Screening for Hepatitis B In recognition of World Hepatitis Day on July 28, the Hepatitis B Foundation (HBF) is calling for all Americans to be tested for hepatitis B infection. The formal recommendation was approved by HBF’s Scientific and Medical Advisory Board to achieve the World Health Organization’s (WHO) ambitious goal of eliminating hepatitis B by the year 2030. Read more. Hepatitis B Leaders Call for the Elimination of Hepatitis B Hep B United, a national coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO) to address the silent epidemic of hepatitis B, hosts its sixth annual summit in Washington, D.C., July 24 to 26. The summit brings together community leaders, advocates and people with hepatitis B to promote screening and prevention strategies and advocate for equitable access to health care to further its mission to eliminate hepatitis B in the United States. Read more. Hepatitis B Foundation Releases New #justB Stories to Empower People Affected by Hepatitis B, Raise Awareness and End Stigma The Hepatitis B Foundation released seven new videos as part of its national #justB storytelling campaign, which was launched one year ago to highlight the personal stories of people from across the United States who have been affected by hepatitis B. Read more Hepatitis B Foundation Honors Business Leader Fred Beans and Scientist Ding-Shinn Chen at its 2018 Crystal Ball Gala The Hepatitis B Foundation (HBF) hosted over 230 leaders from academia, industry, government and the community at its annual Crystal Ball Gala on April 6, 2018 at Pinecrest Country Club in Lansdale, PA. Read more. New Two-Dose HBV Vaccine Recommended by ACIP February 22, 2018: The Advisory Committee on Immunization Practices’ (ACIP) voted today to unanimously recommend HEPLISAV-B™ for use among individuals age 18 years and older to prevent hepatitis B infection (HBV). The Hepatitis B Foundation welcomes the use of the new vaccine, which is expected to increase immunization rates for adults in the United States. Read more. Timothy M. Block, PhD, President of Hepatitis B Foundation and its Baruch S. Blumberg Institute, named a 2017 National Academy of Inventors Fellow 2017 December 12, 2017: Timothy M. Block, Ph.D, has been named a Fellow of the US National Academy of Inventors (NAI), the organization announced Tuesday. Dr. Block is President of the Hepatitis B Foundation, as well as its research arm, the Baruch S. Blumberg Institute, and its Pennsylvania Biotechnology Center. Read more. Hepatitis B Foundation Applauds FDA Approval of New Hepatitis B Vaccine November 2017: Today on World Immunization Day, the Hepatitis B Foundation applauded the U.S. Food and Drug Administration’s (FDA) approval of HEPLISAV-B™, the first new hepatitis B vaccine in more than 25 years and the only two-dose schedule for the prevention of infection in adults. Read more. CDC National Progress Report on Hepatitis Elimination Reveals Rise in Acute HBV Infections and Low Birth Dose Vaccination Rates in the U.S. October 2017: The Hepatitis B Foundation statement on the CDC's national progress report on viral hepatitis elimination in the U.S., which measures progress toward 2020 goals. Read more. Hepatitis B Foundation Announces Promotion of Chari Cohen, DrPH, MPH, to Vice President, Public Health and Programs October 2017: The Hepatitis B Foundation, a national nonprofit organization headquartered in Doylestown, PA, has announced the promotion of Chari Cohen, DrPH, MPH to vice president, public health and programs. Read more. Hepatitis B Foundation Mourns the Loss of Pioneering Hepatitis B Physician-Scientist Dr. W. Thomas London  June 2017: W. Thomas London, MD, an internationally renowned physician-scientist dedicated to the study of hepatitis B, passed away June 3 at the age of 85. Dr. London was a key member of the research team that discovered the hepatitis B virus in the early 1960s, and longtime member of the Board of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute, where he also served as a distinguished scientific and medical advisor. Read more. Hepatitis B Foundation Launches Hep B Cure Campaign for Increased NIH Funding May 2017: The Hepatitis B Foundation launches its national Hep B Cure Campaign, which features a consensus research agenda that outlines top scientists’ priority research recommendations for hepatitis B and liver cancer. Read more. Hepatitis B Foundation's #justB Campaign Gives Voice to Personal Stories During May Hepatitis Awareness Month May 2017: The Hepatitis B Foundation has launched its innovative #justB Storytelling Campaign to highlight the personal stories of people affected by hepatitis B to capture public attention during May Hepatitis Awareness Month. Read more. Hepatitis B Foundation Executive Director Retires After 25 Years of Service April 2017: Co-founder Joan Block helped create the nation’s leading nonprofit research and disease advocacy organization dedicated to hepatitis B. Read more. Hepatitis B Foundation Commends Targets to Eliminate Hepatitis B in U.S. March 2017: The Hepatitis B Foundation commends the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) report, A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report, that concludes a 50 percent reduction in mortality from chronic hepatitis B infection, as well as elimination of mother-to-child transmission of hepatitis B, is possible in the United States by 2030with appropriate prioritization and resources. Read more. Hepatitis B Foundation and HBV Forum Summary Report of Meeting with US FDA  March 2017: Representatives from the Hepatitis B Foundation and HBV Forum met with representatives from the US FDA to discuss clinical development of hepatitis B therapeutics. Read the meeting summary.  Fred Beans Family of Dealerships Donates $30,000 to Support the Hepatitis B Foundation's High School Enrichment Programs February 2017: The Hepatitis B Foundation’s (HBF) High School Science Enrichment Program received a $30,000 donation from the Fred Beans Family of Dealerships to support its research program for outstanding high school students. Read more. Hepatitis B Foundation Welcomes International Leaders to Its Scientific and Medical Advisory Board February 2017: The Hepatitis B Foundation is pleased to announce that two internationally renowned experts in the area of viral hepatitis have joined its Scientific and Medical Advisory Board. Read more. Hepatitis B Foundation Appoints Global Expert Dr. Nat Brown to Its Board of Directors February 2017: The Hepatitis B Foundation, the nation’s leading nonprofit research and disease advocacy organization, is pleased to announce the appointment of Nathaniel Brown, M.D., a retired pharmaceutical executive living in San Francisco, to its Board of Directors. Read more. Hepatitis B Foundation Launches #justB Storytelling Campaign January 2017: The Hepatitis B Foundation unveils its #justB national storytelling campaign with real people sharing their stories about hepatitis B. The goal is to put a human face on this disease in order to increase public awareness, decrease stigma and discrimination, and to promote testing and treatment for hepatitis B, which will ultimately save lives. Read more. World-Renowned Cancer Physician Scientist Dr. Richard G. Pestell Joins the Baruch S. Blumberg Institute January 2017: World-renowned cancer physician scientist Richard G. Pestell, M.D., Ph.D., has joined the Baruch S. Blumberg Institute to serve as President of the Pennsylvania Cancer and Regenerative Medicine Research Center (PCARM). Read more.   Hepatitis B Research Pioneer Dr. Bud Tennant Leaves Behind a Distinguished Scientific Legacy Nov. 2016: Bud C. Tennant, DVM, a pioneer in developing the woodchuck animal model for the study of hepatitis B, and distinguished member of the Hepatitis B Foundation’s Scientific and Medical Advisory Board, passed away on November 16. Read more. Hepatitis B Foundation Co-Sponsors East Coast Film Premiere of Be About It Nov. 2016: Documentary about two families profoundly affected by hepatitis B will show at Philadelphia Asian American Film Festival on November 20. Read more. Hepatitis B Foundation Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection Oct. 2016: Collaboration with Eiger Biopharma and ARUP Laboratories Focuses on Deadly Form of Viral Hepatitis. Read more. Living with Hepatitis B: Hepatitis B Foundation Launches Patient Storytelling Campaign October 2016: National nonprofit creates program to help people living with hepatitis B share their stories. Read more. Hepatitis B Foundation Applauds CMS Final Decision to Cover Hepatitis B Screening September 2016: Hepatitis B screening test added as a preventive service for Medicare beneficiaries. Read more. Hepatitis B Foundation Launches Comprehensive New Website to Celebrate 25th Anniversary September 2016: National nonprofit’s new website offers improved user experience, simplified navigation as a trusted global authority for information about hepatitis B. Read more. Baruch S. Blumberg Institute Congratulates Michael J. Sofia on Receiving the 2016 Lasker-DeBakey Clinical Medical Research Award September 2016: Blumberg Institute professor receives celebrated scientific honor for his discovery of the cure for chronic hepatitis C infection. Read more. Hepatitis B Foundation Partners with Eiger BioPharmaceuticals to Raise Awareness of Hepatitis Delta Virus Co-Infection August 2016: Occurring only in those already infected with hepatitis B, hepatitis delta can lead to more severe liver disease than HBV alone. Read more.  ‘Making the Link’ Between Viral Hepatitis and Liver Cancer July 2016: Hepatitis B Foundation to urge Philadelphia city leaders to help decrease liver cancer rates by making chronic HBV and HCV testing and treatment a local priority. Read more. Hepatitis B Foundation Marks 25th Anniversary at 2016 Crystal Ball Gala April 2016: Annual event raises nearly $125,000 for research and outreach to eliminate hepatitis B that affects more than 12 million Americans and 2 billion people worldwide. Read more. Hepatitis B Foundation’s ‘Nobel Challenge’ Raises $3 Million to Support Research for a Cure Jan. 26 – The Hepatitis B Foundation announces the successful completion of its “Nobel Challenge” campaign, raising more than $3 million to recruit top scientists to its affiliated Baruch S. Blumberg Institute to fulfill its research mission - to find a cure for hepatitis B. Read more.   Baruch S. Blumberg Institute Partners with The Commonwealth Medical College to Offer Innovative Graduate Program Jan. 14 - The Baruch S. Blumberg Institute, established by the Hepatitis B Foundation, announced today it will partner with The Commonwealth Medical College to offer the first life sciences graduate program in Bucks County, PA. Working professionals will be able to earn a Master's degree in Biological Sciences in 16 months during evening and weekend classes at the Blumberg Institute in Doylestown, PA. Read more.   Hepatitis B Foundation Leaders Help Shape National Plan to Eliminate Hepatitis B and C Jan. 11, 2016 - Drs. Robert Gish and Chari Cohen of the Hepatitis B Foundation provide expert testimony to the National Academy of Medicine in support of a national strategy to eliminate chronic viral hepatitis in the United States by 2030. Read more.   Journal of the National Cancer Institute (JNCI) Publishes Summary of Hepatitis B Foundation’s Liver Cancer Workshop Dec. 2015 - The JNCI paper submitted by the Hepatitis B Foundation in collaboration with thought leaders in the field focused on improving screening and care for those with liver cancer related to chronic hepatitis B infections. The article, “Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care,” has been published online and will appear in the NCI Journal’s print issue in April 2016. Read more.   The W. Thomas London Distinguished Professorship Established by the Hepatitis B Foundation and Baruch S. Blumberg Institute Oct. 2015 - The named Professorship honors Dr. W. Thomas London (on left) who made transformational contributions to the discovery of the hepatitis B virus with Dr. Baruch Blumberg and dedicated his career to the study of the virus and care of those affected. Dr. Ju Tao Guo (on right) is the inaugural recipient of the new professorship. He serves as director of Experimental Therapeutics at the Baruch S. Blumberg Institute, which was established by the Hepatitis B Foundation to fulfill its research mission. Read more. 2015 Press Releases Dr. Eugene Schiff Receives Hepatitis B Foundation’s Highest Scientific Honor April 20 – The 2015 Crystal Ball Gala, hosted by the Hepatitis B Foundation, was a huge success, and included an evening of dinner, dancing, live and silent auctions, a mission moment, and the awarding of the Baruch S. Blumberg Prize to Dr. Eugene Schiff for advancing the care and treatment of chronic hepatitis B. Read more.   Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists March 2015 – The Baruch S. Blumberg Institute (www.blumberginstitute.org) has recruited a new team of nationally renowned scientists to focus exclusively on research to develop a cure for hepatitis B, a move that nearly triples its research capacity and has created the largest concentration of nonprofit scientists focusing solely on hepatitis B and liver cancer in the United States. Read more.   Hepatitis B Foundation Welcomes Two New Board Members Jan 26 – The HBF is proud to announce that Craig Esterly, engineer and business owner, and Wayne Yetter, pharmaceutical industry executive, have joined its Board of Directors. Both bring broad and deep experience in the healthcare arena, and are joining the Foundation at a time when we are rapidly expanding and accelerating our pace of research into finding a cure for hepatitis B. Read more.

  https://www.hepb.org/news-and-events/news-2/